-+ 0.00%
-+ 0.00%
-+ 0.00%

Annexon Hosts Virtual Investor Event on Phase 3 ARCHER II Trial

PUBT·10/28/2026 12:09:16
Listen to the news
Annexon Hosts Virtual Investor Event on Phase 3 ARCHER II Trial
  • Annexon will host a virtual investor event on Nov. 3, 2026, at 11 a.m. ET.
  • Presentations will focus on the Phase 3 ARCHER II trial of vonaprument for geographic atrophy, including trial design and patient demographics.


Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Annexon Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202610280800PRIMZONEFULLFEED9854387) on October 28, 2026, and is solely responsible for the information contained therein.